Prevalence and control of hypertension among diabetes patients in hospital universiti sains malaysia, malaysia
Abstract
Hypertension in patients with type 2 diabetes mellitus is a prevalent condition that leads to substantial morbidity and mortality. The aim of the study was to determine the prevalence of hypertension in type 2 diabetes attending endocrinology clinics at Hospital Universiti Sains Malaysia (HUSM), to describe antihypertensive treatment patterns, and to evaluate the target of blood pressure achieved by antihypertensive agents. The study was a prospective follow-up descriptive study. Study conducted at diabetic clinic outpatient at HUSM, Kelantan, Malaysia from January to December 2007. A total of 1077 diabetic patients involve in this study. The findings of our study showed that the majority patients type 2 diabetes mellitus 998 (92.7 %) had hypertension. For the patients who were on antihypertensive medications, 254 (23.6 %) of them were on monotherapy and 311 (28.9 %), 179 (16.6 %), and 198 (18.4 %) respectively received two, three and more than three antihypertensive agents. The majority of patients 872 (87.4 %) were on angiotensin converting enzyme inhibitors/angiotensin receptor blockers either alone or in combination with other antihypertensive drugs. A number of 601 (55.8 %) patients achieved blood pressure targets ≤ 130/80 mm Hg. Almost all patients with hypertension and
diabetes will require a combination of antihypertensive medications. A number of patients was not achieved blood pressure goals ≤ 130/80 mm Hg. There is still need to educate both patients and health care providers of importance of achieving target of blood pressure in order to reduce morbidity and mortality in diabetes mellitus patients.
Key words: Hypertension, type 2 diabetes mellitus, hypertension treatmentFull Text:
PDF 121-128References
ALLHAT Collaborative Research Group, 2002, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, ,288, 2981–2997.
American Diabetes Association, 2002, Standards of medical care for patients with diabetes mellitus, Diabetes Care, 25, 213
Amos, A. F., McCarty, D. J., and Zimmet, P., 1997, The rising global burden of diabetes and its complications: estimates and projections to the year 2010, Diab. Med.,14 (Suppl. 5),S81–85.
Arauz-Pacheco, C., Parrott, M.A., and Raskin, P., 2003, American Diabetes Association. Treatment of hypertension in adults with diabetes, Diabetes Care, 26, Suppl 1, S80-82
Bakris, G. L., Fonseca, V., and Katholi, R. E., 2004, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial, JAMA, 292, 2227–2236.
Burt, V. L., Cutler, J. A., Higgins, M., Horan. M. J., Labarthe, D., and Whelton, P., 1995, Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from the Health Examination Survey, 1960-1991, Hypertension,155,1855-1860.
Dahlof, B., Sever, P. S., and Poulter, N. R., 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial, Lancet,366, 895–906.
Douglas, J. G., Bakris, G. L., and Epstein, M., 2003, Management of high blood pressure in African Americans: consensus statement of the Hypertension in African AmericansWorking Group of the International Society on Hypertension in Blacks, Arch. Intern. Med.,163, 525–541.
Grossman, E., and Messerli, F.H., 1996, Diabetic and hypertensive heart disease, Ann Intern Med, 125, 304–310.
Grossman, E., Messerli, F. H., and Goldbourt, U., 2000, High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?, Arch. Intern. Med., 160, 2447–2452
Hyman, D. J., and Pavlik, V. N. , 2001, Characteristics of patients with uncontrolled hypertension in the United States, N. Eng. J. Med., 345, 479-486.
Klauser, R., Prager, R., and Gaube, S., 1991, Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus, Hypertension,17, 15–21.
Kjeldsen, S. E., Os, I., and Hoieggen, A.,2005, Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide, Am. J. Cardiovasc. Drugs, 5, 17–22.
Ministry of Health of Malaysia, 2002, Clinical practice guidelines on the management of hypertension 2002
Rosenbloom, A. L., Joe, J. R., Young, R. S., and Winter, W. E., 1999, Emerging epidemic of type 2diabetes in youth, Diabetes Care, 22, 345–354.
Schrier, R. W., Estacio, R. O., and Esler, A,, 2002, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes, Kidney Int., 61,1086-1097.
UKPDS Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group, Br. Med. J.,317,703–713.
Vijan, S., and Hayward, R. A., 2003, Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care, Ann. Intern. Med., 138, 593-602
Whelton, P. K., Barzilay, J., and Cushman, W. C., 2005, Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Arch. Intern. Med.,165,1401–1409.
World Health Organization,1999, International Society of Hypertension guidelines for the management of hypertension, J. Hypertens., 17,151-183.
Zimmet, P. Z., 1995, The pathogenesis and prevention of diabetes in adults: Genes, autoimmunity, and demography, Diabetes Care,18,1050-1064.
DOI: http://dx.doi.org/10.14499/indonesianjpharm0iss0pp121-128
Refbacks
- There are currently no refbacks.
Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Indonesian J Pharm indexed by: